REPUBBLICA ITALIANAIl Tribunale Amministrativo Regionale per il Veneto(Sezione Terza)ha pronunciato la presenteORDINANZASul ricorso numero di registro generale 245 del 2010, proposto da: Razzismo Stop Associazione Onlus, rappresentato e difeso dall'avv. Michele Dell'Agnese, con domicilio presso la Segreteria del T.A.R., ai sensi dell'art. 35 R.D. 26 giugno 1924, n. 1054;controil Comune di Selvaz
Microsoft word - ajaybhatnagar.docCURRICULUM VITAE
Ajay Sahai BHATNAGAR
Date of Birth:
Citizenship: Switzerland Marital Status: Education and Degrees:
University of Basel, Switzerland, Ph.D.
University of Cambridge, England, M.A.
University of Cambridge, England B.A. (Hons.)
Council of Scientific and Industrial Research For more information and interaction contact Advanced Strategies Pvt. Ltd. http://www.astrategies.com firstname.lastname@example.org +91-22-22672561 Current and Academic Appointments:
2001 to date
Head, Global Business Continuity Planning Novartis Pharma AG, CH-4002 Basel, Switzerland Novartis Pharma AG, CH-4002 Basel, Switzerland Preclinical Development & Project Management Novartis Pharma AG, CH-4002 Basel, Switzerland Head, Research Planning & Operations Ciba-Geigy Limited, CH-4002 Basel, Switzerland Ciba-Geigy Limited, CH-4002 Basel, Switzerland Assistant Professor (tenured July 1, 1978) Department of Obstetrics & Gynecology and Professional Societies:
♦ American Association for the Advancement of Science ♦ New York Academy of Sciences ♦ The ♦ Swiss Society for Endocrinology ♦ British Endocrine Society ♦ American Physiological Society ♦ Society for the Study of Reproduction Activities in Ciba-Geigy Limited and Novartis Pharma AG from 1984 to
Joined Ciba-Geigy as Preclinical Project Leader of Aromatase Inhibitor Project and Deputy Head, Endocrine Research Head, Endocrine Research and Member, International Project Teams for the development of the Aromatase Inhibitors Formestane (Lentaron®), Fadrozole (Afema®) and Letrozole (Femara®) Preclinical Project Leader of the 5α-Reductase Inhibitor Project Preclinical Expert for Registration of Lentaron®, Member of Core Registration Team Preclinical Expert for the Registration of Estraderm MX and other transdermal systems for hormone replacement therapy. Responsibility for the RIA Lab involved in the measurement of all serum hormones in the clinical development of transdermal systems for HRT. Appointed International Project Team Leader for Letrozole (Femara®) as well as Head, Research Planning & Operations, Pharma Research Center Basel Appointed Preclinical Expert and Member Core Registration Team for Letrozole (Femara®) 1996 Femara® registered in France July 1996 1996 Pharmacological Head, Planning & Administration, Preclinical Development and Project Management Basel Operations, Novartis Pharma AG Nominated Preclinical Expert for Femara® and Member of Femara International Project Team Project Manager, Project Year 2000 Pharma Basel Head, Global Business Continuity Planning
Author of over 50 publications in peer-reviewed journals, several reviews, chapters in books and editor of one book.
Board Certified in Gastroenterology Nick Sharma, M.D. Brian D. Feiock, M.D. Brian E. Longendyke, D.O. Michael Weiss, M.D. Michael W. Bays, D.O. Srinivas Raju, M.D. Ramesh Koka, M.D. Tal Hazan, M.D. Julian Perez, M.D. PEPTIC ULCER DISEASE INTRODUCTION — Peptic ulcer disease (PUD) is a chronic (long lasting) condition that affects